secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K/A
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001193125-23-082149
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience discloses compensation for interim CEO Scott Giacobello: quarterly bonus, option grant
--------------------------------------------------------------------------------

- Scott Giacobello appointed Interim CEO and President effective March 15, 2023; remains CFO.
- Quarterly bonus of $43,000 (prorated) approved for interim role.
- Eligible for annual cash bonus at 90% of base salary based on performance objectives.
- Received stock option for 100,000 shares vesting over 4 years with standard schedule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523082149/0001193125-23-082149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312523082149/d492554d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-082149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer